20/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) ? Clinical Center

Medicine & Life Sciences

1. Metformin 100%
2. Type 2 Diabetes Mellitus 87%
3. Health Care Outcome Assessment 66%
4. Life Style 47%
5. Glucose Intolerance 42%
6. Volunteers 37%
7. Cardiovascular Diseases 28%
8. Population 26%
9. Diabetes Complications 22%
10. Gestational Diabetes 21%
11. Risk Reduction Behavior 19%
12. National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) 19%
13. Placebos 18%
14. Controlled Clinical Trials 17%
15. Clinical Trials 12%
16. Minority Groups 12%
17. Therapeutics 11%
18. Vulnerable Populations 9%
19. Public Health 9%
20. Islets of Langerhans 9%
21. Hispanic Americans 9%
22. Mental Competency 9%
23. Morbidity 8%
24. African Americans 8%
25. Hyperglycemia 8%
26. Atherosclerosis 8%
27. Insulin Resistance 7%
28. Mortality 7%
29. Economics 7%
30. Weight Loss 7%
31. B-Lymphocytes 7%
32. Outpatients 7%
33. Data Analysis 7%
34. Blood Vessels 6%
35. Medicine 6%
36. Occupational Groups 6%
37. Research Personnel 6%
38. Diet 6%
39. Exercise 6%
40. Hypertension 6%
41. Glucose 5%
42. Hemoglobins 5%
43. Costs and Cost Analysis 5%